Mitochondrial-derived peptides: New markers for cardiometabolic dysfunction.
Fiche publication
Date publication
décembre 2021
Journal
Archives of cardiovascular diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COTTIN Yves, Pr VERGELY Catherine
Tous les auteurs :
Rochette L, Rigal E, Dogon G, Malka G, Zeller M, Vergely C, Cottin Y
Lien Pubmed
Résumé
Great attention is being paid to the evaluation of new markers in blood circulation for the estimation of tissue metabolism disturbance. This endogenous disturbance may contribute to the onset and progression of cardiometabolic disease. In addition to their role in energy production and metabolism, mitochondria play a main function in cellular mechanisms, including apoptosis, oxidative stress and calcium homeostasis. Mitochondria produce mitochondrial-derived peptides that mediate the transcriptional stress response by translocating into the nucleus and interacting with deoxyribonucleic acid. This class of peptides includes humanin, mitochondrial open reading frame of the 12S ribosomal ribonucleic acid type c (MOTS-c) and small humanin-like peptides. Mitochondrial-derived peptides are regulators of metabolism, exerting cytoprotective effects through antioxidative stress, anti-inflammatory responses and antiapoptosis; they are emerging biomarkers reflecting mitochondrial function, and the circulating concentration of these proteins can be used to diagnose cardiometabolic dysfunction. The aims of this review are: (1) to describe the emerging role for mitochondrial-derived peptides as biomarkers; and (2) to discuss the therapeutic application of these peptides.
Mots clés
Biomarkers, Biomarqueurs, Cardiometabolic, Cardiométabolique, Humanin, Humanine, Mitochondrial-derived-peptides, Oxidative stress, Peptides mitochondriaux, Stress oxydatif
Référence
Arch Cardiovasc Dis. 2021 Dec 28;: